UNILIFE CORPORATION (NASDAQ:UNIS) Files An 8-K Regulation FD Disclosure

Item7.01.

On November17, 2016, Unilife Corporation (the Company) posted to
the Investors link at www.unilife.com an investor
presentation attached to this report as Exhibit 99.1 (the
Investor Presentation). The Company intends to use the Investor
Presentation at the Jefferies Global Healthcare Conference at
4:40 p.m. GMT (11:40 a.m. EST) on November17, 2016.

The information hereunder shall not be deemed to be filed for
purposes of Section18 of the Securities Exchange Act of 1934 (the
Exchange Act) or otherwise subject to the liabilities of that
section, nor shall it be incorporated by reference into a filing
under the Securities Act of 1933, or the Exchange Act, except as
shall be expressly set forth by specific reference in such a
filing.

2

About UNILIFE CORPORATION (NASDAQ:UNIS)

Unilife Corporation is engaged in the designing, development and manufacturing of injectable drug delivery systems. The Company has a portfolio of product platforms, including pre-filled syringes, disposable and reusable auto-injectors, drug reconstitution delivery systems, ocular delivery systems, and other systems for the targeted delivery of injectable therapies. The majority of its products are designed for sale directly to pharmaceutical and biotechnology companies supplying them as drug-device combination products, pre-filled and ready for administration by end-users, such as health-care providers or patients. Its other products, such as reusable auto-injectors and certain systems for targeted drug delivery are designed either to be sold to pharmaceutical or biotechnology companies for use as combination products or to be sold directly to a health care provider or end user without having the device pre-filled by a pharmaceutical company.

UNILIFE CORPORATION (NASDAQ:UNIS) Recent Trading Information

UNILIFE CORPORATION (NASDAQ:UNIS) closed its last trading session up +0.02 at 2.96 with – shares trading hands.